IL6 and neoplasm: IL-6 promotes PD-L1 expression in human hepatocellular carcinoma (HCC) through the JAK/STAT3 signaling pathway, thereby reducing the expression of protein tyrosine phosphatase receptor and further promoting tumor immune escape (67).